Stockscreener 앱 받기
9.58
0.21%
0.02
시간 외 거래:
9.58
전일 마감가:
$9.56
열려 있는:
$9.65
하루 거래량:
257.46K
Relative Volume:
0.86
시가총액:
$316.06M
수익:
-
순이익/손실:
$-62.31M
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-6.45%
1개월 성능:
-21.54%
6개월 성능:
-39.02%
1년 성능:
+0.00%
1일 변동 폭
$9.3644
$9.77
1주일 범위:
$9.226
$10.40
52주 변동 폭
$9.226
$22.33
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
명칭
Lexeo Therapeutics Inc
전화
(212) 547-9879
주소
345 PARK AVENUE SOUTH, NEW YORK
Lexeo Therapeutics Inc 주식(LXEO)의 최신 뉴스
Objective long/short (LXEO) Report - Stock Traders Daily
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $22.14 Consensus Price Target from Analysts - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Short Interest Update - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of “Buy” by Analysts - Defense World
Gene Therapies For Cardiomyopathies Market Growth Anticipated - openPR
The Globe and Mail - The Globe and Mail
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 5,000 Shares - MarketBeat
Lexeo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Lexeo Therapeutics to Participate in Upcoming Investor Conferences - StockTitan
Top investors say Lexeo Therapeutics Inc. (LXEO) ticks everything they need - SETE News
The Lexeo Therapeutics Inc. (LXEO) had a good session last reading, didn’t it? - US Post News
Short Interest in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Expands By 16.9% - MarketBeat
Trading (LXEO) With Integrated Risk Controls - Stock Traders Daily
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $22.14 Average Price Target from Analysts - MarketBeat
Chardan Capital Comments on Lexeo Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:LXEO) - MarketBeat
Vanguard Group Inc. Grows Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Stifel maintains 'Buy' on Lexeo stock, confident amid trial progress By Investing.com - Investing.com Canada
Chardan Capital Weighs in on Lexeo Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:LXEO) - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Stock Rating Reaffirmed by Chardan Capital - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Expected to Earn Q3 2024 Earnings of ($0.64) Per Share - MarketBeat
Q3 2024 Earnings Estimate for Lexeo Therapeutics, Inc. Issued By Leerink Partnrs (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Expected to Earn Q3 2024 Earnings of ($0.64) Per Share - Defense World
Royal Bank of Canada Reiterates Outperform Rating for Lexeo Therapeutics (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics (NASDAQ:LXEO) Posts Quarterly Earnings Results, Hits Estimates - MarketBeat
Lexeo Therapeutics CEO sells $57.6k in company stock By Investing.com - Investing.com Australia
Lexeo Therapeutics (NASDAQ:LXEO) Given "Buy" Rating at Chardan Capital - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Price Target Lowered to $21.00 at HC Wainwright - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 5,000 Shares of Stock - Defense World
Lexeo Therapeutics CEO sells $57.6k in company stock - Investing.com
Lexeo Therapeutics (NASDAQ:LXEO) Given New $21.00 Price Target at HC Wainwright - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Given "Outperform" Rating at Royal Bank of Canada - MarketBeat
Comparing Cognition Therapeutics (NASDAQ:CGTX) & Lexeo Therapeutics (NASDAQ:LXEO) - Defense World
LXEO Stock Earnings: Lexeo Therapeutics Beats EPS for Q2 2024 - InvestorPlace
LXEO Stock Earnings: Lexeo Therapeutics Beats EPS for Q2 2024 - MSN
Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights - GlobeNewswire
Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights - StockTitan
Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights - Yahoo Finance
Lexeo Therapeutics Inc.’s latest rating changes from various analysts - Knox Daily
American International Group Inc. Invests $79,000 in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Contrasting Lexeo Therapeutics (NASDAQ:LXEO) & Kiromic BioPharma (NASDAQ:KRBP) - Defense World
Janus Henderson Group PLC Acquires 210,047 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Robert W. Baird gives an Outperform recommendation for Lexeo Therapeutics Inc. (LXEO) - Knox Daily
BNP Paribas Financial Markets Takes Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
LXEO (Lexeo Therapeutics Inc.) may reap gains as insiders became active recently - Knox Daily
Lexeo Therapeutics Inc. (LXEO) deserves closer scrutiny - US Post News
Lexeo Therapeutics, Inc. to Post Q3 2024 Earnings of ($0.59) Per Share, Leerink Partnrs Forecasts (NASDAQ:LXEO) - Defense World
Q3 2024 EPS Estimates for Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Decreased by Analyst - MarketBeat
Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates - Yahoo Finance
Lexeo Down Despite Upbeat Rare Disease Gene Therapy Data - Markets Insider
Lexeo Therapeutics Inc (LXEO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
1.31%
자본화:
|
볼륨(24시간):